What have researchers discovered about ROR1 and its role in targeted CLL therapies? Andrew Schorr hosts coverage from the 2017 American Society of Hematology (ASH) conference to learn about the latest innovations in CLL research and treatment. Tune in to hear Dr. Michael Choi, from the UCSD Moores Cancer Center, discuss ROR1 and its innovative role in targeted therapies for CLL. He also shares new approved treatments and opportunities for patients to get involved with clinical trials currently being conducted.
ROR1: An Update From ASH 2017
